Nov/Dec 2015: Volume 16 Number 11/12

15th European AIDS Conference (EACS), 21-24 October 2015, Barcelona

Remarkable results with dolutegravir monotherapy

First-line ART with dolutegravir plus 3TC: 24-week early results

New European HIV guidelines (October 2015): universal ART, first-line integrase and PrEP

Impact of early ART on lung function: results on ART and COPD from START substudy

No difference in neuropsychological test results between early and delayed ART in START substudy

Immediate ART in START linked to greater bone loss over three years

Price of MDR TB drugs could be greatly reduced with competitive generic manufacture

Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

French cohort of HIV transgender women highlights issues relating to HIV management

7th International Workshop on HIV Paediatrics, 17-18 July, Vancouver, Canada

Substituting lopinavir/ritonavir with efavirenz in children on stable ART

The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression

Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB

CHAI’s ARV market report predicts that new drugs and formulations will drive the next major drop in treatment costs

New trade agreements threaten treatment access in Asia

Tenofovir alafenamide (TAF) approved – but only as part of a fixed dose combination

European HIV guidelines updated (October 2015)

New UK guidelines on use of vaccines in HIV positive adults (2015)

IAS-USA update resistance guidelines and mutation tables (2015)

HIV rates still increasing in gay men: 2015 report

PrEP to be available free in France from January 2016

PrEP efficacy for transgender women: new analysis from iPrEX study

PrEP in a clinical setting: no infections reported in San Francisco cohort

New free self-sampling HIV home testing service launched in England

NICE decision on ledipasvir/sofosbuvir for chronic HCV

Sofosbuvir/velpatasvir submitted to US FDA for HCV genotype 1-6

US indication for ledipasvir/sofosbuvir expanded

Why START would make an excellent long-term cohort

Why dolutegravir might get us closer to ending AIDS: next step, further research

November/December 2015: Volume 16 Number 11/12

September/October 2015: Volume 16 Number 9/10

Sept/Oct 2015: Volume 16 Number 9/10

Two new i-Base resources: Introduction to ART booklet and a Pocket ART leaflet

55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-21 September 2015, San Diego

No transmission of integrase-resistant HIV seen in California cohort

Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor

Protection against flu but not HBV in vaccinated perinatally HIV-infected children

8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19-22 July 2015, Vancouver, Canada

The PrEP experience: IAS 2015 and beyond

Raltegravir for neonates will require a complicated dosing regimen

News and notes on HIV cure research from IAS 2015

16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 26-28 May 2015, Washington DC

Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel

Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives

Pharmacokinetics of four antiretrovirals in pregnancy: data from the PANNA network

Dolutegravir placental transfer moderate in ex vivo model

Paediatric dosing of DRV/r

Why the 5000% price hike for pyrimethamine in the US is relevant in the UK

Proposed TTIP trade agreement in Europe: Report shows European Commission’s access to medicines commitments are ‘empty gestures’

FDA approve additional weight band dosing for children using atazanavir powder

UK BHIVA treatment guidelines for HIV positive adults (2015)

WHO guidelines for when to start ART and use of PrEP (September 2015)

Neurocognitive disorder, persistent inverted CD4:CD8 ratios and immune activation in the CNS

i-Base Q&A resources on PrEP: increased use of off-label PrEP in the UK shows need for NHS support and risk to PEP services

Two new UK community PrEP websites

First UK NHS PrEP support service launched at 56 Dean Street, Soho

UK PROUD study published as open access article in The Lancet: PrEP dramatically reduces risk of HIV

Gilead to provide free hepatitis drugs to treat all people liviing with hepatitis C in Iceland

Australian doctors advice for buying generic sofosbuvir for HepC

Combining PKC agonists and bromodomain inhibitors to reverse HIV latency

Estimating how frequently latent HIV reactivates

Professor Clive Loveday awarded a Royal Order of Chivalry

Post navigation